Acumen Pharmaceuticals Inc.

Biotechnology company dealing with neurodegenerative diseases - developing effective medicines and diagnostics for Alzheimer’s disease and memory loss

Founded in 1996, Acumen Pharmaceuticals Inc. has established collaborations with Northwestern University and Merck Research Laboratories. The company is located in California, USA.

David Summa, President and CEO
Grant A. Krafft, Ph.D., CSO
William F. Goure, Ph.D., COO

Grant A. Krafft, Ph.D., Chairman
Mark A. Cochran, Ph.D.
Mark Lampert
Daniel J. O’Connell
David Summa
Jürgen Weber, Ph.D. MBA

Caleb Finch, Ph.D.
Carl W. Cotman, Ph.D.
Leon J. Thal, M.D.
Tony Giordano, Ph.D.
Vijay Pande, Ph.D.
William L. Klein, Ph.D.

385 Oyster Point Blvd., Suite 9A
South San Francisco, CA, 94080
USA
Phone: +1-650-875-7700
Fax: +1-650-875-7772

Acumen Pharmaceuticals focuses on neurodegenerative diseases and escpecially Alzheimer’s disease (AD). The company’s target compound, termed ADDL, is supposed to have neurotoxic properties and block essential pathways in nerve cells.

As high ADDL concentrations could be found in AD brain cells compared to healthy cells, the first idea was to use ADDL for the diagnosis of Alzheimer’s disease. Acumen also works on the development of treatment options, including active immunotherapy and the use of small molecules as assembly blocker of ADDL.